Return to News

COSMIC News

COSMIC_actionability_logo_1.png

NEW Product coming soon: COSMIC Actionability!

24 Nov 2020

We have recently launched The Cancer Mutation Census to much acclaim and success! But at COSMIC we never stop! Now we are working on our next product, Mutation Actionability in Precision Oncology!

Responsive design preview banner.png

What is Mutation Actionability in Precision Oncology?
The aim of COSMIC Mutation Actionability in Precision Oncology product (Actionability) is to indicate the availability of drugs that target mutations in cancer and track the progress of clinical studies towards making new drugs available. Drugs that target somatic mutations are represented at all stages of drug development, through safety and clinical phases to market and repurposing, with additional case studies.

The principal units of actionability are mutation, disease, and drug. Capturing relations between these units allows identification of existing and upcoming drugs that target particular genetic variants in specific cancer types.

Actionability youtube play graphic.png












We have created a short video introduction which can be watched here.


Our approach to actionability curation

  • Clinical trial records
    Freely available however often incomplete or outdated.

  • Literature/journal articles
    Actionability data is manually curated by experienced PhD level experts. This approach identifies trial outcomes that are not available in clinical trials databases, adding almost 3x more data.

  • Company websites
    We look for otherwise unpublished data in conference abstracts and corporate websites, to offer the fullest possible picture.

  • FDA
    We include details of all trials submitted to the FDA for mutation-specific approved drugs.

Would you like to get involved and find out more?

If you are interested in finding out more and helping us improve the Actionability resource, please get in touch. We really value your opinion and would like to share an interactive prototype with you and any interested colleagues, in exchange for any feedback you may have to offer. Please email Charlie Hathaway, User Experience Lead on cosmicengagement@sanger.ac.uk for further information.

Keep up date to with COSMIC

Please follow us on LinkedIn, Twitter, Facebook and via our email announcements to keep abreast of the latest COSMIC news and developments. If you do not receive our emails, please update your email preferences, as shown below, in your COSMIC account.

Email preferences graphic.jpg


About

COSMIC, the Catalogue Of Somatic Mutations In Cancer, is the most comprehensive resource for exploring the impact of somatic mutations in human cancer. Here on our news page we aim to give you an insight into what we are doing and why. We will keep you updated with new developments and release information as well as any events we are hosting.

Tags

release

workshop

website

curation

COSMIC-3D

vacancies

downloads

user experience

data submission

website update

Cancer Gene Census

mutation ID

Hallmarks of Cancer

GRCh37

drug resistance

GRCh38

video

tutorial

birthday

International Women's Day

literature

mutational signatures

Mesothelioma

conference

AACR

gene

Bile duct cancer

cholangiocarcinoma

Europe PMC

Service announcement

blog

survey

updates

v90

search

cosv

updated

CDS

Fasta

cDNA

disease focus

world cancer day

new product

cmc

DIAS

Actionability

COSMIC

webinar

introduction to cosmic

mutations

celebrating success

Oncology

oncology trials

precision medicine

clinical trials

precision oncology

cancer

genomics

immuno oncology

breast cancer

cosmic v95

bioinformatics

cancermutationcensus

COSMICv95

Lung Cancer

Glioblastoma

testicular cancer

cancer prevention

biomarkers

Cancer Research

tumour microenvironment

copy number variants

ageing

genes

genome

clones

smoking

Clonal haematopoesis

tumour

inherited

disease

individuals

risk

variants

leukaemia

Myelodysplastic syndrome

lymphoma

haematological cancers

Myeoloproliferative neoplasms

myeloma

haematological

somatic mutations

blood cancers

blood cancer

NRAS

acral lentiginous melanoma

BRAF

melanoma

driver gene

skin cancer

uv light

Mexico

chromosome

acral melanoma

breed predisposition

genetics

PIK3CA

driver genes

canine cancer

data ecosystem

database

canine

tumour board

barrett's oesophagus

oesophageal cancer

upper gi

gene panel

cell lines project

Wellcome Sanger Institute

sanger

uv radiation

uv nail lamp

SBS18

reactive oxygen species

DNA damage

uv damage

sebaceous gland carcinoma

Kaposi cell carcinoma

Lynch syndorme

carcinoma

cancerresearch

Merkel cell carcinoma

Muir-torres syndrome

MLH1

sanger institute

Mike Stratton

cancer genome project

BRCA2

mutographs

resistance mutations

IWD24

Women in STEM

IT

computational biology

STEM career

computer science